ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD.BMC psychiatry · 2022Article
- Increased mGlu5 mRNA expression in BLA glutamate neurons facilitates resilience to the long-term effects of a single predator scent stress exposure.Brain structure & function · 2021Article
- Patterns of Cannabis Use Among Individuals with Obsessive-Compulsive Disorder: Results from an Internet Survey.Journal of obsessive-compulsive and related disorders · 2021Article
- Meet Your Stress Management Professionals: The Endocannabinoids.Trends in molecular medicine · 2020Review
- CBInternational journal of molecular sciences · 2020Article
- Quantification of the Cannabinoid Type 1 Receptor Availability in the Mouse Brain.Frontiers in neuroanatomy · 2020Article
- Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Review
- Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.Acta pharmacologica Sinica · 2019Review
- The neuropsychopharmacology of cannabis: A review of human imaging studies.Pharmacology & therapeutics · 2019Review
- Intrinsic Frontolimbic Connectivity and Mood Symptoms in Young Adult Cannabis Users.Frontiers in public health · 2019Article
- Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma.Chronic stress (Thousand Oaks, Calif.) · 2019Article
- A Review of the Neurobiological Basis of Trauma-Related Dissociation and Its Relation to Cannabinoid- and Opioid-Mediated Stress Response: a Transdiagnostic, Translational Approach.Current psychiatry reports · 2018Review
- Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression.Frontiers in molecular neuroscience · 2018Article
- Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors.Scientific reports · 2017Article
- Medical Marijuana and the Treatment of Post Traumatic Stress Disorder: A Survey of Michigan Psychiatrists' Opinions.Spartan medical research journal · 2017Article
- Neurobiology of comorbid post-traumatic stress disorder and alcohol-use disorder.Genes, brain, and behavior · 2017Review
- Maintenance of aversive memories shown by fear extinction-impaired phenotypes is associated with increased activity in the amygdaloid-prefrontal circuit.Scientific reports · 2016Article
- The rs1049353 polymorphism in the CNR1 gene interacts with childhood abuse to predict posttraumatic threat symptoms.The Journal of clinical psychiatry · 2015Article
- Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder.Psychoneuroendocrinology · 2015Review
Corrections and comments
- Retraction · 2020-09-08Falsification/Fabrication of Data · Falsification/Fabrication of Results · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · · Alexander Neumesiter has ORI finding of misconduct;
- Commented on by
- Retracted
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Attentional bias to threat is a key endophenotype that contributes to the chronicity of trauma-related psychopathology. However, little is known about the neurobiology of this endophenotype and no known in vivo molecular imaging study has been conducted to evaluate candidate receptor systems that may be implicated in this endophenotype or the phenotypic expression of trauma-related psychopathology that comprises threat (ie, re-experiencing, avoidance, and hyperarousal) and loss (ie, emotional numbing, depression/dysphoria, generalized anxiety) symptomatology. Using the radioligand [(11)C]OMAR and positron emission tomography (PET), we evaluated the relationship between in vivo cannabinoid receptor type 1 (CB1) receptor availability in the amygdala, and performance on a dot-probe measure of attentional bias to threat, and clinician interview-based measures of trauma-related psychopathology. The sample comprised adults presenting with a broad spectrum of trauma-related psychopathology, ranging from nontrauma-exposed, psychiatrically healthy adults to trauma-exposed adults with severe trauma-related psychopathology. Results revealed that increased CB1 receptor availability in the amygdala was associated with increased attentional bias to threat, as well as increased severity of threat, but not loss, symptomatology; greater peripheral anandamide levels were associated with decreased attentional bias to threat. A mediation analysis further suggested that attentional bias to threat mediated the relationship between CB1 receptor availability in the amygdala and severity of threat symptomatology. These data substantiate a key role for compromised endocannabinoid function in mediating both the endophenotypic and phenotypic expression of threat symptomatology in humans. They further suggest that novel pharmacotherapies that target the CB1 system may provide a more focused, mechanism-based approach to mitigating this core aspect of trauma-related psychopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.